Type of information: Licensing agreement
Compound: lentiviral vectors to treat haemophilia
Company: Oxford Biomedica (UK) Bioverativ (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: licensing - collaboration
Action mechanism: gene therapy
- • On February 15, 2018, Oxford BioMedica announced that it has completed a major new collaboration & licence agreement with Bioverativ for the development and manufacturing of lentiviral vectors to treat haemophilia. The agreement includes a licence to use OXB’s LentiVector Enabled technology and access to its industrial-scale manufacturing technology.
- Under the terms of the agreement, Oxford BioMedica will receive a $5 million upfront payment from Bioverativ. Oxford BioMedica is also eligible to receive various milestone payments, potentially worth in excess of $100 million, and undisclosed royalties on net sales of Bioverativ’s lentiviral vector haemophilia products. Bioverativ will also fund process development and scale-up activities for its lentiviral vector haemophilia products at Oxford BioMedica. The agreement also allows for the parties to put in place a clinical supply agreement for GMP manufacturing of haemophilia products at Oxford BioMedica.